Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements

Gaetano Ruocco, Mauro Feola, Ranuccio Nuti, Lorenzo Luschi, Isabella Evangelista, Alberto Palazzuoli, Gaetano Ruocco, Mauro Feola, Ranuccio Nuti, Lorenzo Luschi, Isabella Evangelista, Alberto Palazzuoli

Abstract

Background: Despite the fact that loop diuretics are a landmark in acute heart failure (AHF) treatment, few trials exist that evaluate whether the duration and timing of their administration and drug amount affect outcome. In this study, we sought to evaluate different loop diuretic infusion doses in relation to outcome and to diuretic response (DR), which was serially measured during hospitalization.

Methods: This is a post-hoc analysis of a DIUR-HF trial. We divided our sample on the basis of intravenous diuretic dose during hospitalization. Patients taking less than 125 mg of intravenous furosemide (median value) were included in the low dose group (LD), patients with a diuretic amount above this threshold were inserted in the high dose group (HD). The DR formula was defined as weight loss/40 mg daily of furosemide and it was measured during the first 24 h, 72 h, and over the whole infusion period. Outcome was considered as death due to cardiovascular causes or heart failure hospitalization.

Results: One hundred and twenty-one AHF patients with reduced ejection fractions (EF) were evaluated. The cardiovascular (CV) death/heart failure (HF) re-hospitalization rate was significantly higher in the HD group compared to the LD group (75% vs. 22%; p < 0.001). Both low DR, measured during the entire infusion period (HR 3.25 (CI: 1.92-5.50); p < 0.001) and the intravenous diuretic HD (HR 5.43 [CI: 2.82-10.45]; p < 0.001) were related to outcome occurrence. Multivariable analysis showed that DR (HR 3.01 (1.36-6.65); p = 0.006), intravenous diuretic HD (HR 2.83 (1.24-6.42); p=0.01) and worsening renal function (WRF) (HR 2.21 (1.14-4.28); p = 0.01) were related to poor prognosis.

Conclusions: HD intravenous loop diuretic administration is associated with poor prognosis and less DR. Low DR measured during the whole intravenous administration better predicts outcome compared to DR measured in the early phases. ClinicalTrials.gov Acronym and Identifier Number: DIUR-HF; NCT01441245; registered on 23 September 2011.

Keywords: acute heart failure; congestion; diuretic response; loop diuretics; outcome.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Receiving operating characteristics (ROC) curve analysis for 180 days outcome prediction of IV furosemide dosage (A); ROC curve analysis for 180 days outcome prediction of lower DR measured at day 1, at day 3 and during whole IV infusion (B).
Figure 2
Figure 2
Kaplan Meier 180 days survival curves in patients divided into high vs. low IV furosemide doses (A); Kaplan Meier 180 days survival curves in patients divided into high vs. low DR measurements during entire infusion period (B).

References

    1. Felker G.M., O’Connor C.M., Braunwald E. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil? Circ. Heart Fail. 2009;2:56–62. doi: 10.1161/CIRCHEARTFAILURE.108.821785.
    1. Gupta S., Neyses L. Diuretic usage in heart failure: A continuing conundrum in 2005. Eur. Heart J. 2005;26:644–649. doi: 10.1093/eurheartj/ehi176.
    1. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., Falk V., González-Juanatey J.R. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016;18:891–975.
    1. Felker G.M., Lee K.L., Bull D.A., Redfield M.M., Stevenson L.W., Goldsmith S.R. Diuretic strategies in acute decompensated heart failure. N. Engl. J. Med. 2011;364:797–805. doi: 10.1056/NEJMoa1005419.
    1. Testani J.M., Brisco M.A., Turner J.M., Spatz E.S., Bellumkonda L., Parikh C.R., Tang W.H. Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ. Heart Fail. 2014;7:261–270. doi: 10.1161/CIRCHEARTFAILURE.113.000895.
    1. Peacock W.F., Costanzo M.R., De Marco T., Lopatin M., Wynne J., Mills R.M., Emerman C.L. ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: Insights from the ADHERE registry. Cardiology. 2009;113:12–19. doi: 10.1159/000164149.
    1. Ter Maaten J.M., Dunning A.M., Valente M.A., Damman K., Ezekowitz J.A., Califf R.M., Starling R.C., van der Meer P., O’Connor C.M., Schulte P.J., et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am. Heart J. 2015;170:313–321. doi: 10.1016/j.ahj.2015.05.003.
    1. Ter Maaten J.M., Rao V.S., Hanberg J.S., Perry Wilson F., Bellumkonda L., Assefa M., Sam Broughton J., D’Ambrosi J., Wilson Tang W.H., Damman K., et al. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur. J. Heart Fail. 2017;19:1014–1022. doi: 10.1002/ejhf.757.
    1. Makadia S., Simmons T., Augustine S., Kovell L., Harris C., Chibungu A., Parakh K. The diuresis clinic: A new paradigm for the treatment of mild decompensated heart failure. Am. J. Med. 2015;128:527–531. doi: 10.1016/j.amjmed.2014.11.028.
    1. Valente M.A., Voors A.A., Damman K., Van Veldhuisen D.J., Massie B.M., O’Connor C.M., Metra M., Ponikowski P., Teerlink J.R., Cotter G., et al. Diuretic response in acute heart failure: Clinical characteristics and prognostic significance. Eur. Heart J. 2014;35:1284–1293. doi: 10.1093/eurheartj/ehu065.
    1. Voors A.A., Davison B.A., Teerlink J.R., Felker G.M., Cotter G., Filippatos G., Greenberg B.H., Pang P.S., Levin B., Hua T.A., et al. Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome—An analysis from RELAX-AHF. Eur. J. Heart Fail. 2014;16:1230–1240. doi: 10.1002/ejhf.170.
    1. Palazzuoli A., Testani J.M., Ruocco G., Pellegrini M., Ronco C., Nuti R. Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int. J. Cardiol. 2016;224:213–219. doi: 10.1016/j.ijcard.2016.09.005.
    1. Damman K., Testani J.M. The kidney in heart failure: An update. Eur. Heart J. 2015;36:1437–1444. doi: 10.1093/eurheartj/ehv010.
    1. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., Kusek J.W., Van Lente F. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006;145:247–254. doi: 10.7326/0003-4819-145-4-200608150-00004.
    1. Gheorghiade M., Follath F., Ponikowski P., Barsuk J.H., Blair J.E., Cleland J.G., Dickstein K., Drazner M.H., Fonarow G.C., Jaarsma T., et al. Assessing and grading congestion in acute heart failure: A scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur. J. Heart Fail. 2010;12:423–433. doi: 10.1093/eurjhf/hfq045.
    1. Campbell P.T., Ryan J. Diuretic dosing in acute decompensated heart failure: Lessons from DOSE. Curr. Heart Fail. Rep. 2012;9:260–265. doi: 10.1007/s11897-012-0094-8.
    1. Hanberg J.S., Tang W.H.W., Wilson F.P., Coca S.G., Ahmad T., Brisco M.A., Testani J.M. An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. Int. J. Cardiol. 2017;241:277–282. doi: 10.1016/j.ijcard.2017.03.114.
    1. Abdel-Qadir H.M., Tu J.V., Yun L., Austin P.C., Newton G.E., Lee D.S. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am. Heart J. 2010;160:264–271. doi: 10.1016/j.ahj.2010.05.032.
    1. Shah R.V., McNulty S., O’Connor C.M., Felker G.M., Braunwald E., Givertz M.M. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from diuretic optimization strategies in acute heart failure. Am. Heart J. 2012;164:862–868. doi: 10.1016/j.ahj.2012.08.019.
    1. House A.A., Haapio M., Lassus J., Bellomo R., Ronco C. Therapeutic strategies for heart failure in cardiorenal syndromes. Am. J. Kidney Dis. 2010;56:759–773. doi: 10.1053/j.ajkd.2010.04.012.
    1. Francis G.S., Siegel RMGoldsmith S.R., Olivari M.T., Levine T.B., Cohn J.N. Acute vasoconstriction response to intravenous furosemide in patients with chronic congestive heart failure. Activation of neurohormonal axis. Ann. Intern. Med. 1985;103:1–6. doi: 10.7326/0003-4819-103-1-1.
    1. Hasselblad V., Stough W.G., Shah M.R., Lokhnygina Y., O’Connor C.M., Califf R.M., Adams K.F., Jr. Relation between dose of loop diuretics and outcomes in heart failure population: Results of the ESCAPE trial. Eur. J. Heart Fail. 2007;9:1064–1069. doi: 10.1016/j.ejheart.2007.07.011.
    1. Pellicori P., Cleland J.G., Zhang J., Kallvikbacka-Bennett A., Urbinati A., Shah P., Kazmi S., Clark A.L. Cardiac Dysfunction, Congestion and Loop Diuretics: Their Relationship to Prognosis in Heart Failure. Cardiovasc. Drugs Ther. 2016;30:599–609. doi: 10.1007/s10557-016-6697-7.
    1. Yilmaz M.B., Gayat E., Salem R., Lassus J., Nikolaou M., Laribi S., Parissis J., Follath F., Peacock W.F., Mebazaa A. Impact of diuretic dosing on mortality in acute heart failure using a propensity matched study. Eur. J. Heart Fail. 2011;13:1244–1252. doi: 10.1093/eurjhf/hfr121.
    1. Fedele F., Severino P., Calcagno S., Mancone M. Heart failure: TNM-like classification. J. Am. Coll. Cardiol. 2014;63:1959–1960. doi: 10.1016/j.jacc.2014.02.552.
    1. Aronson D., Burger A.J. Diuretic Response: Clinical and Hemodynamic Predictors and Relation to Clinical Outcome. J. Card. Fail. 2016;22:193–200. doi: 10.1016/j.cardfail.2015.07.006.
    1. Rao V.S., Planavsky N., Hanberg J.S., Ahmad T., Brisco-Bacik M.A., Wilson F.P., Jacoby D., Chen M., Tang W.H.W., Cherney D.Z.I., et al. Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure. J. Am. Soc. Nephrol. 2017;28:3414–3424. doi: 10.1681/ASN.2016111178.
    1. Palazzuoli A., Ruocco G., Ronco C., McCullough P.A. Loop diuretics in acute heart failure: Beyond the decongestive relief for the kidney. Crit. Care. 2015;19:296. doi: 10.1186/s13054-015-1017-3.
    1. Aoki S., Okumura T., Sawamura A., Kitagawa K., Morimoto R., Sakakibara M., Murohara T. Usefunless of the combination of in-hospital poor diuretic response and systemic congestion to predict future cardiac events in patients with acute decompensated heart failure. Am. J. Cardiol. 2017;119:2010–2016. doi: 10.1016/j.amjcard.2017.03.030.
    1. Mullens W., Damman K., Harjola V.P., Mebazaa A., Brunner-La Rocca H.P., Martens P., Testani J.M., Tang W.H.W., Orso F., Rossignol P., et al. The use of diuretics in heart failure with congestion—A position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21:137–155. doi: 10.1002/ejhf.1369.
    1. Palazzuoli A., Ruocco G., Vescovo G., Valle R., Di Somma S., Nuti R. Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR-AHF. ESC Heart Fail. 2017;4:479–486. doi: 10.1002/ehf2.12226.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren